Free Trial
OTCMKTS:USRM

U.S. Stem Cell (USRM) Stock Price, News & Analysis

U.S. Stem Cell logo
$0.0001 0.00 (0.00%)
As of 04/1/2025 09:30 AM Eastern

About U.S. Stem Cell Stock (OTCMKTS:USRM)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
$0.0002
Volume
1,000 shs
Average Volume
212,564 shs
Market Capitalization
$66,150.70
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Remove Ads
Receive USRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

USRM Stock News Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Headlines

USRM Stock Analysis - Frequently Asked Questions

U.S. Stem Cell's stock was trading at $0.0001 at the start of the year. Since then, USRM shares have increased by 0.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

U.S. Stem Cell, Inc. (OTCMKTS:USRM) issued its earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share (EPS) for the quarter. The business earned $1.30 million during the quarter.

Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that U.S. Stem Cell investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Auxly Cannabis Group (CBWTF), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX).

Company Calendar

Last Earnings
8/07/2019
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
OTCMKTS:USRM
Previous Symbol
NASDAQ:BHRT
Employees
11
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
550,903,000
Market Cap
$66,150.70
Optionable
Not Optionable
Beta
-1.28

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (OTCMKTS:USRM) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners